VEYONDA - Registered Trade Mark for NOX66

Date: 20 August 2018 Sydney, Australia ASX Limited 20 Bridge Street SYDNEY NSW 2000 VEYONDA REGISTERED TRADE MARK FOR NOX66 Sydney, 20 August 2018: Noxopharm (ASX: NOX) today announces that the trade mark, Veyonda, has been approved in Australia as part of a world-wide application. NOX66 is due to embark next year on its final stages of clinical development with a series of multi -national studies including a propos ed Phase 3 registration study. In view of this, it was considered timely to trade mark the name, Veyonda, ahead of the drug’s anticipated eventual commercial release. About Veyonda Veyonda (previously known as NOX66) contains the active drug candidate, idronoxil (IDX). Veyonda is being developed as a unique enhancer of radiotherapy based on 3 integrated actions: (#1) mitotic arrest, resulting in cancer cells being held in a state where their DNA is particularly sensitive to radiation-induced damage; (#2) blocking the ability of the cancer cell to repair dama ged DNA; and (#3) non-specific activation of natural killer (NK) cells, part of the body’s primary defence against tumour cells. Veyonda is being developed for use in patients with late -stage solid cancers who are receiving palliative radiotherapy. The cancers being targeted in the first instance are prostate cancer (metastatic castrate-resistant disease), lung cancer, brain cancer and sarcomas. Veyonda has 2 objectives: the first is to rely on actions #1 and #2 above to achieve greater response (shrinkage) in irradiated tumours; the second is to rely on action #3 to achieve a response in non - irradiated tumours (abscopal response). Both responses have been achieved in current clinical studies with Veyonda, with delays in disease progression and better survival the targeted outcomes. About Noxopharm Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy . NOX66 is the first pipeline product, with later generation drug candidates under development. Investor & Corporate Enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 9299 9690 E: [email protected] E: [email protected] ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office and Operational Office: Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia Board of Directors Mr Peter Marks Chairman Non-Executive Director Dr Graham Kelly Chief Executive Officer Managing Director Dr Ian Dixon Non-Executive Director Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projection s and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward -looking statements to be reasonable, they are not certain. Forward -looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward -looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward -looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

The release as fetched from its publisher. noxopharm.com ↗